The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment

J Med Virol. 2023 Jan;95(1):e28330. doi: 10.1002/jmv.28330.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • HIV Infections* / drug therapy
  • Humans
  • Pyridones / therapeutic use
  • Rilpivirine / therapeutic use

Substances

  • Rilpivirine
  • cabotegravir
  • Pyridones
  • Anti-HIV Agents